HUTCHMED (China) Limited is a biopharmaceutical firm dedicated to the discovery, advancement, and marketing of innovative targeted and immune-based treatments for various cancers and immune-related disorders. Its operations are divided into two main areas: Oncology/Immunology and a segment encompassing Other Ventures. The company's reach extends from Hong Kong globally. Among its pipeline, HUTCHMED is developing Savolitinib, an inhibitor targeting non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC). Another key therapeutic,…
13 analysts rate HCM Buy on consensus.
Consensus price target: $20.59 (+44.19% upside from $14.28)
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $549.96M | -12.73% | $458.12M |
| 2024 | $630.2M | -24.8% | $37.73M |
| 2023 | $838M | +96.52% | $100.78M |
Stock data for HCM: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics